In 2016, Nicolazzo et al. first demonstrated the connection between PD-L1 positive circulating tumor cells (PD-L1+CTCs) and poorer survival in non-small cell lung cancer (NSCLC) patients treated with nivolumab [6]. This evidence concerns the gene CD274 and neoplasm.